Skip to main content

Advertisement

Table 1 Patients’ characteristics at baseline

From: Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period

   Summary statistics
Age (n = 35) At the beginning of the study 53.32 (13.63) (22.23;74)
Number of patients ≥ 65 years (LORA) 8/35 (22.86%)
Gender (n = 35) Female 24/35 (68.57%)
Disease duration (n = 35) Duration from initial diagnosis until inclusion in the study (in months) 0.2 (0.42) (0;1.98)
Duration of symptoms (in months) 1.3 (1.25) (0.13;4.5)
Disease Activity Score 28 (DAS28) DAS28(ESR) (n = 34) 5.55 (1.11) (3.55;7.57)
DAS28(CRP) (n = 31) 5.02 (1.12) (3.09;6.77)
Laboratory parameters ESR (1 h/mm) (n = 34) 39.62 (22.23) (8;95)
CRP (n < 5.0 mg/l) (n = 32) 16.34 (17.89) (0;66.52)
Clinical examination (n = 35) Swollen joint count (28-SJC) 6.31 (4.73) (1;20)
Tender joint count (28-TJC) 10.26 (7.85) (1;25)
VAS (0–100 mm) for disease activity Patient (n = 35) 58.14 (18.79) (20;100)
Physician (n = 21) 54.52 (16.58) (30;90)
Rheumatoid factor (RF) Seropositive (n = 34) 15/35 (42.86%)
Rheumatoid factor IgA (n = 29) 93.23 (166.03) (0.1;500)
Rheumatoid factor IgM (n = 31) 59.64 (113.93) (0.1;500)
Anti-citrullinated peptide antibodies (ACPA) (n = 35) Level 250.34 (393.27) (0.42;1000)
Positive 4/35 (11.43%)
Highly positive 15/35 (42.86%)
  1. Patients’ characteristics at baseline: mean (SD); (min; max) or n (%); DAS28 Disease Activity Score of 28 joints, ESR erythrocyte sedimentation rate, CRP C-reactive protein